Home Stock

Stock Research: Edwards Lifesciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Edwards Lifesciences

NYQ:EW US28176E1082
50
  • Value
    7
  • Growth
    83
  • Safety
    Safety
    96
  • Combined
    79
  • Sentiment
    19
  • 360° View
    360° View
    50
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Edwards Lifesciences Corporation is a global company focused on structural heart disease. The company operates in the medical devices industry with products including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It operates in the United States, Europe, Japan, and the Rest of World. In the last fiscal year, the company had 15800 employees, a market cap of $45057 million, profits of $4322 million, and revenue of $5440 million.

more

ANALYSIS: With an Obermatt 360° View of 50 (better than 50% compared with alternatives), overall professional sentiment and financial characteristics for the stock Edwards Lifesciences are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Edwards Lifesciences. The consolidated Growth Rank has a good rank of 83, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 83% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 96 which means that the company has a financing structure that is safer than 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 7 which means that the share price of Edwards Lifesciences is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 93% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 19, which means that professional investors are more pessimistic about the stock than for 81% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Liquidity
Country USA
Industry Health Care Equipment
Size X-Large
Website edwards.com
Index
D.J. US Health Care
D.J. US Medical Equipment
S&P 500
Edwards Lifesciences stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
7 13 10 5
Growth
83 23 51 91
Safety
Safety
96 100 93 77
Sentiment
19 58 39 54
360° View
360° View
50 25 51 72
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
41 24 14 30
Opinions Change
34 67 38 53
Pro Holdings
n/a 86 72 38
Market Pulse
16 46 59 85
Sentiment
19 58 39 54
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
7 13 10 5
Growth
83 23 51 91
Safety Safety
96 100 93 77
Combined
79 29 64 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
17 13 18 9
Price vs. Earnings (P/E)
14 29 34 27
Price vs. Book (P/B)
31 43 16 19
Dividend Yield
1 1 1 1
Value
7 13 10 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
50 60 43 47
Profit Growth
87 21 36 53
Capital Growth
38 25 86 86
Stock Returns
73 49 55 97
Growth
83 23 51 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
89 83 76 67
Refinancing
29 44 17 7
Liquidity
100 100 100 96
Safety Safety
96 100 93 77

Similar Stocks

Discover high‑ranked alternatives to Edwards Lifesciences and broaden your portfolio horizons.

FedEx

NYQ:FDX
Country: USA
Industry: Air Freight & Logistics
Size: XX-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews